-- Scilex (SCLX) 週二宣布，其子公司 ACEA Therapeutics 已同意以 10 億美元的全股票交易方式，將其持有的 ACEA Pharma 100% 股權轉讓給 Phoenix Asia (PHOE)。 根據協議，ACEA Therapeutics 將獲得 1 億股新發行的 Phoenix 股票，每股價格為 10 美元，以換取其持有的 ACEA Pharma 股權。 交易完成後，Phoenix 將更名為 ACEA Pharma，其普通股預計將在納斯達克上市。 ACEA Therapeutics 預計將保留合併後公司約 82% 的股權。 該交易預計將於第二季完成。 週二下午交易中，Scilex (SCLX) 股價下跌近 5%，而 Phoenix Asia 股價上漲 23%。
Price: $10.64, Change: $-0.52, Percent Change: -4.62%
Major digital assets rose Tuesday with Bitcoin (BTC-USD) topping $81,000.The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, rose almost 1.3% in the past 24 hours. The Nasdaq 100 was up 1.4%, the S&P 500 rose 0.9%, and the Dow Jones Industrial Average added 0.9%.Bitcoin rose 2% to $81,657, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume decreased 34% to $37.2 billion.Ethereum (ETH-USD), the second-largest digital asset by market value, added 0.8% to $2,375.XRP (XRP-USD) gained 1%, BNB (BNB-USD) rose 1.1%, and Solana (SOL-USD) added 2.4%. Dogecoin (DOGE-USD) climbed 2.9%, while Cardano (ADA-USD) was up 2.9%.The US 10-year Treasury yield stood at 4.413% at 3 p.m. ET Tuesday, down from 4.447% Monday, while the five-year yield fell to 4.069% from 4.093%.The total market value of the cryptocurrency industry rose 1.7% in the past 24 hours to $2.69 trillion, with trading volume gaining 1.8% to $164.38 billion.Price: $81530.92, Change: $+1706.70, Percent Change: +2.14%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price to $70 from $83, on a P/E of 7.8x our 2027 EPS view vs. the peer average of 6.7x. We decrease our 2026 EPS view to $8.14 from $8.28 and 2027's to $9.00 from $9.17. Despite operational challenges, FISV maintained its 2026 guidance and commitment to shareholder returns. The company affirmed its expectation for organic revenue growth of 1%-3% and adjusted EPS of $8.00-$8.30 for 2026. FISV repurchased $200M worth of shares in Q1, demonstrating continued confidence in its long-term prospects. This confidence is directly tied to the tangible progress made under the "One Fiserv" action plan. Management highlighted key operational improvements, such as a 27% Y/Y reduction in client inquiry resolution time and strong underlying growth in platforms like Finxact and CommerceHub, as leading indicators that support the full-year guidance. We think the positive underlying trends will become more visible in the financial results in 2H 2026 and beyond.
Peng Lu, Chief Medical Officer, on May 01, 2026, sold 14,166 shares in Pharvaris (PHVS) for $427,419. Following the Form 4 filing with the SEC, Lu has control over a total of 66,083 common shares of the company, with 66,083 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526206273/xslF345X05/ownership.xmlPrice: $29.94, Change: $-0.08, Percent Change: -0.27%